Harmony Biosciences Preannounces Record $261M Q2 Revenue, Reaffirms $1B+ Guidance, CFO Steps Down
HRMY sits 36% above its 52-week low of $25.52.
Summary
Harmony Biosciences preannounced Q2 2026 net product revenue of approximately $261 million, a record quarter driven by 30% year-over-year growth in WAKIX sales. The company reaffirmed its full-year 2026 revenue guidance of $1.0 billion to $1.04 billion. CFO Glenn Reicin has stepped down effective immediately, with Controller Stephen Mollichella serving as interim principal financial officer. The CFO departure follows a pattern of insider selling by the former CFO, but the company states the transition is not due to any disagreement. Full Q2 results are scheduled for August 4, 2026.
At the time of this announcement, HRMY was trading at $34.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $25.52 to $40.87. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: BusinessWire.